Directory Calendar News Careers Alumni Giving

Greg Yothers, PhD

Research Associate Professor, Biostatistics

Director, NRG Oncology SDMC, Division of Biostatistics and Science, Pittsburgh


201 N Craig St, Suite 350, NRG Oncology SDMC
R-znvy: tnlfg8@cvgg.rqh
Primary Phone: 967-838-7003
Fax: 967-838-6832
Web site:

Personal Statement

My primary research interest is the design, implementation and analysis of phase II and III clinical trials for cancer research.  My work with the NRG Oncology clinical trials cooperative group has included trials evaluating therapies for the treatment of colon and rectal cancer.  The focus of my methodological research has been the development of statistical methodologies for identifying a subset of a clinical trial or population where a treatment is effective. 


I am the Director of the Division of Biostatistics and Science for the Pittsburgh office of the NRG Oncology Statistics and Data Management Center - leadership role in maintaining effective operations to support numerous clinical trials in a research group comprising 200 employees.  I have sole responsibility for the program of research in colorectal cancer as well as increasing responsibilities in the breast and prostate cancer disease sites. 


2003 | University of Pittsburgh, Pittsburgh, PA | Doctor of Philosophy in Statistics

1998 | University of Pittsburgh, Pittsburgh, PA | Master of Arts in Statistics
1981 | Pennsylvania State University, State College, PA | Bachelor of Science in Mathematics

Selected Publications


Blum, J. L., Flynn, P. J., Yothers, G., Asmar, L., Geyer, C. E.,
Jacobs, S. A., . . . Wolmark, N. (2017). Anthracyclines in Early Breast
Cancer: The ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49
(NRG Oncology).. J Clin Oncol,
JCO2016714147. doi:10.1200/JCO.2016.71.4147

Kunitake, H., Russell, M. M., Zheng, P., Yothers, G., Land, S.
R., Petersen, L., . . . Ganz, P. A. (2017). Quality of life and symptoms in
long-term survivors of colorectal cancer: results from NSABP protocol LTS-01.
JOURNAL OF CANCER SURVIVORSHIP, 11(1), 111-118. doi:10.1007/s11764-016-0567-y

Sinicrope, F. A., Shi, Q., Allegra, C. J., Smyrk, T. C.,
Thibodeau, S. N., Goldberg, R. M., . . . Alberts, S. R. (2017). Association
of DNA Mismatch Repair and Mutations in BRAF and KRAS With Survival After
Recurrence in Stage III Colon Cancers : A Secondary Analysis of 2 Randomized
Clinical Trials. JAMA oncology, 3(4), 472-480. doi:10.1001/jamaoncol.2016.5469

Song, N., Pogue-Geile, K. L., Gavin, P. G., Yothers, G., Kim, S.
R., Johnson, N. L., . . . Paik, S. (2016). Clinical outcome from oxaliplatin
treatment in stage II/III colon cancer according to intrinsic subtypes:
Secondary analysis of NSABP C-07/NRG oncology randomized clinical trial. JAMA Oncology, 2(9), 1162-1169. doi:10.1001/jamaoncol.2016.2314

Cheung, W. Y., Renfro, L. A., Kerr, D., De Gramont, A., Saltz,
L. B., Grothey, A., . . . Sargent, D. J. (2016). Determinants of
earlymortality among 37,568 patientswith colon cancerwho participated in 25
clinical trials from the adjuvant colon cancer endpoints database. Journal of Clinical Oncology, 34(11), 1182-1189. doi:10.1200/JCO.2015.65.1158

Shah, M. A., Renfro, L. A., Allegra, C. J., André, T., De
Gramont, A., Schmoll, H. J., . . . Sargent, D. J. (2016). Impact of patient
factors on recurrence risk and time dependency of oxaliplatin benefit in
patients with colon cancer: Analysis from modern-era adjuvant studies in the
adjuvant colon cancer end points (ACCENT) database. Journal of Clinical Oncology, 34(8),
843-853. doi:10.1200/JCO.2015.63.0558

Link to Greg Yothers complete bibliography...

Greg  Yothers
© 2018 by University of Pittsburgh Graduate School of Public Health

Login  |  Sitemap